Introduction {#S1}
============

Levothyroxine (LT~4~) is the standard therapeutic choice in hypothyroidism replacement therapy ([@B1]). Representing the synthetic equivalent of native tetraiodothyronine (T~4~), LT~4~ modulates the same biological functions ([@B2]). In the literature, several peripheral markers have been proposed to measure the peripheral response to thyroid hormones (THs), such as lipid profile \[total cholesterol (CH), low density lipoprotein CH, and lipoprotein(a)\], coagulation parameters (plasminogen activator inhibitor), hepatic protein synthesis indexes \[sex hormone-binding globulin (SHBG) and ferritin\], muscular system (creatine phosphokinase and myoglobin), bone metabolism parameters (osteocalcin and urinary N-telopeptide), and selected enzymatic activity \[angiotensin-converting enzyme (ACE) and glucose-6-phosphate dehydrogenase\] ([@B2]).

LT~4~ is administered orally, dissolved by gastric acids and absorbed mainly in jejunum and ileum ([@B1]). Many factors influence LT~4~ absorption, such as food and beverages ([@B3]--[@B5]), drugs ([@B6]--[@B13]), and pathological conditions impairing the digestive tract absorptive ability ([@B7], [@B14], [@B15]). Moreover, several drugs are able to interfere with TH requirements increasing LT~4~ metabolism and clearance ([@B4]), or acting on expression and activity of catabolic enzymes ([@B16]).

The LT~4~ activation and inactivation occur through the action of deiodinases ([@B17]). Reversible sulfotransferases and glucuronyltransferases mediate the inactivation of TH in the liver, increasing iodothyronines water-solubility, promoting biliary and urinary clearance ([@B17]). In the bowel, gut bacteria expressing β-glucuronidases and sulfatase enzymes are able to hydrolyze glucuronidated and sulfated iodothyronines metabolites ([@B17], [@B18]). In this way, lipophilic deconjugated iodothyronines can be reabsorbed, constituting the enterohepatic recycle of THs ([@B17], [@B18]). According to this mechanism, LT~4~ requirement could be regulated acting on intestinal bacteria and modifying THs enterohepatic recycle. In this context, gut can be considered a possible reservoir of THs ([@B17]), although a clear *in vivo* demonstration is still lacking.

Probiotics are defined as live microorganisms which, when consumed in adequate amounts, confer a health effect on the host ([@B19]). They are not considered drugs by the current international legislation ([@B19]). Probiotics limit the intestinal colonization from pathogenic bacteria ([@B20], [@B21]), improve the physiological bowel barrier function ([@B20], [@B21]), and influence the pro-inflammatory and anti-inflammatory cytokines production ([@B20]--[@B23]). However, the mechanism by which probiotics contribute to microbiota modulation has not been completely clarified so far ([@B20]). Although an effect of probiotics on health has been proposed in several pathologic conditions ([@B18], [@B20], [@B24]--[@B37]), a clear demonstration is still lacking.

Up to now, there is low evidence of probiotics interaction with concomitant drug ingestion, considering their influence on bacteria enzymatic activity ([@B38], [@B39]). Since products containing probiotics are very popular, it would be important to discover any possible interference with pharmacological therapies. This interaction could result in clinical consequences on LT~4~-treated patients simultaneously taking probiotics. This is the first clinical trial designed to investigate whether a mixture of highly charged *Lactobacilli* and *Bifidobacteria* (VSL\#3^®^) is able to influence LT~4~ metabolism acting on the gut microbiota in hypothyroid patients.

Materials and Methods {#S2}
=====================

A prospective, randomized, single-blind, controlled, investigator-started clinical trial was carried out ([ClinicalTrials.gov](ClinicalTrials.gov) ID: registration number NCT03095963).

Patients' inclusion criteria were: primary hypothyroidism on LT~4~ replacement therapy, thyroid-stimulating hormone (TSH), fT~3~ and fT~4~ in the normal range, stable LT~4~ dosage during the 6 months before enrolment, Caucasian ethnicity, age 18--65 years. Exclusion criteria were total thyroidectomy for thyroid carcinoma, intestinal malabsorption (e.g., bariatric surgery, inflammatory bowel diseases, celiac disease), ongoing therapies interfering with LT~4~ absorption and/or metabolism (i.e., aluminum-containing antacids, sucralfate, proton pump inhibitors, calcium carbonate, raloxifene, bile acids sequestrants, and ferrous sulfate), and antibiotics treatment in the 6 months before enrolment.

Study Design {#S2-1}
------------

Consecutive patients on LT~4~ replacement therapy attending the Endocrinology Unit of Modena (Italy) were screened. According to inclusion and exclusion criteria, 80 participants were enrolled and randomized in study or control group. The random allocation sequence was generated using "Statistical Package for the Social Sciences" software for Macintosh (SPSS) considering a 1:1 ratio by the statistician of the Unit. Clinicians evaluating and enrolling patients were blinded to the randomization list. The study design provided a monthly visit for a 4 months overall time-frame. Patients assigned to the study group took the probiotic supplement VSL\#3^®^ for 2 months, followed by a 2-month period of follow-up (Figure [1](#F1){ref-type="fig"}). All patients were instructed to take LT~4~ tablets with water in the morning with empty stomach, at least 30 min before breakfast and/or other medicine ingestion. Study group patients were taught to assume the probiotic supplement at least 2 h after LT~4~ administration, irrespective of meals, to dissolve it in a cold beverage and to store it in a refrigerator (2--8°C), in order to preserve bacteria load. Patients assigned to the control group continued their LT~4~ therapy without placebo administration.

![Study design.](fendo-08-00316-g001){#F1}

The study design was single-blind since only the clinician was aware of the allocation. The VSL\#3^®^ administration was provided by nurses. Participants were invited to return all used and unused sachets to count the number of opened sachets per the number of treatment days.

All patients underwent five monthly visits (baseline, visit 1, 2, 3, and 4), in which anthropometrical evaluation (weight and height) and hormonal function assessment were performed. A fasting blood sample was taken in the morning at each visit before LT~4~ ingestion. Since TSH results were available the same day of blood sampling, LT~4~ daily dose was promptly adjusted on occurrence of TSH alterations (laboratory reference range: 0.35--4.94 μIU/mL), according to clinical guidelines ([@B40]). At baseline, visit 2, and visit 4, patients underwent clinical examination with heart rate and blood pressure evaluation (Figure [1](#F1){ref-type="fig"}). During each visit, the following data were collected: probiotic ingestion, sex, age, hypothyroidism etiology, LT~4~ formulation dose and brand, body mass index (BMI), body surface area (BSA), systolic blood pressure, diastolic blood pressure, heart rate, TSH, fT~4~, fT~3~, and any possible LT~4~ posology adjustment.

VSL\#3^®^ {#S2-2}
---------

VSL\#3^®^ is a multistrain probiotic supplement available in packets. Each VSL\#3^®^ sachet contains a high concentration (450 × 10^9^ CFU) of live freeze-dried bacteria, belonging to eight different strains, i.e., *Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. The compound was chosen considering its highest concentration among commonly used probiotics-containing products.

Laboratory Analyses {#S2-3}
-------------------

During the 4 months evaluation timeline, thyroid function assessment (TSH, fT~3~, fT~4~) was performed monthly to revise LT~4~ dosage if necessary. Blood samples for each patient at each visit were stored at −20°C° until the end of enrolment, to measure peripheral tissue markers of THs. Table S1 in Supplementary Material summarizes methodologies used for each assay and the respective intra- and inter-assay coefficient of variation.

Statistical Analysis {#S2-4}
--------------------

Considering that no studies so far evaluated the influence of probiotics on hormonal measurements, the sample size was calculated using a previous study aiming at analyzing the influence on LT~4~ absorption. Singh et al. found a TSH decrease of about 70% after concomitant ingestion of calcium and LT~4~ in patients treated for hypothyroidism ([@B41]). Thus, assuming a similar variation of TSH in patients treated with both probiotics and LT~4~, using ANOVA univariate statistical analysis, considering a statistical power of 90% and an α-error of 0.05, the required sample size was of 80 patients. Setting a 1:1 case--control ratio, the final sample size was of 40 patients for each group.

Continuous parameters were compared between study and control groups through ANOVA univariate and/or Mann--Whitney test, according to data distribution, evaluated by Kolmogorov--Smirnov test. Categorical variables were compared with Chi-square or Fisher exact test. The changes after treatment were evaluated considering repeated variables, using Wilcoxon signed-rank test. The degree of correlation between ordinal variables was studied using Spearman rho correlation test.

In order to evaluate THs metabolism and pituitary feedback, fT~3~/fT~4~, fT~3~/TSH, and fT~4~/TSH ratios were calculated. Moreover, hormonal measurements were adjusted for the anthropometrical available variables (BMI and BSA).

Statistical analysis was performed using the "Statistical Package for the Social Sciences" software for Macintosh (version 21.0; SPSS Inc., Chicago, IL, USA). Statistical significance was considered significant when *p* \< 0.05.

Ethical Approval {#S2-5}
----------------

The Institutional Review Board of Modena (Comitato Etico di Modena) approved the study (code 184/13, approved on 12th November 2013).

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent {#S2-6}
----------------

Written informed consent was obtained from all individual participants included in the study.

Results {#S3}
=======

One hundred and twenty hypothyroid patients on LT~4~ replacement therapy were screened and 80 patients were enrolled according to inclusion and exclusion criteria (Figure [2](#F2){ref-type="fig"}). Thirty-nine patients (48.8%) entered the study group and 41 (51.2%) the control group. Baseline characteristics of patients are shown in Table [1](#T1){ref-type="table"}.
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###### 

Patients data and characteristics collected at baseline.

                                           Reference range   Study group     Control group   *p* Value
  ---------------------------------------- ----------------- --------------- --------------- -------------
  Patients number                          --                39              41              --
  Female, *n* (%)                          --                36 (92.3)       41 (100)        0.222
  Male, *n* (%)                            --                3 (7.7)         0 (0)           0.222
  Autoimmune thyroiditis, *n* (%)          --                28 (71.8)       30 (73.2)       0.9160
  Non-autoimmune hypothyroidism, *n* (%)   --                11 (28.2)       9 (22)          0.698
  Post-thyroidectomy, *n* (%)              --                0 (0)           1 (2.4)         0.960
  Post radioiodine, *n* (%)                --                0 (0)           1 (2.4)         0.960
  Eutirox^®^, *n* (%)                      --                37 (94.9)       37 (90.2)       0.718
  Tirosint^®^, *n* (%)                     --                1 (2.6)         3 (7.3)         0.644
  Non-branded LT~4~, *n* (%)               --                1 (2.6)         1 (2.4)         0.496
  Age (years)                              --                49.6 ± 10.39    49.33 ± 11.38   0.791
  BMI (kg/m^2^)                            18.50--24.99      27.77 ± 6.14    27.71 ± 6.12    0.735
  SBP (mmHg)                               90--120           116 ± 14        115 ± 15        0.703
  DBP (mmHg)                               60--80            74 ± 8          73 ± 10         0.809
  Heart rate (bpm)                         60--100           70 ± 6          72 ± 7          ***0.043***
  TSH (μIU/mL)                             0.35--4.94        2.37 ± 1.66     2.72 ± 1.83     0.308
  fT~3~ (pg/mL)                            1.7--3.7          2.7 ± 0.3       2.6 ± 0.3       0.871
  fT~4~ (pg/mL)                            7--15             10.8 ± 1.6      10.9 ± 1.6      0.749
  LT~4~ dose (μg/day)                      --                78.21 ± 26.95   74.56 ± 23.02   0.789
  LT~4~ dose (μg/kg/day)                   --                1.06 ± 0.38     1.08 ± 0.39     0.855

*Data are expressed as mean ± SD. p value is considered significant when \< 0.05*.

*BMI, body mass index; bpm, beats per minute; DBP, diastolic blood pressure; fT~3~, free triiodothyronine; fT~4~, free tetraiodothyronine; LT~4~, levothyroxine; SBP, systolic blood pressure; TSH, thyroid-stimulating hormone*.

At baseline, three male patients (3.75%) entered the study group while no male patients entered the control group. This gender disparity is in line with the known highest female incidence of primary hypothyroidism ([@B1]). Three patients (one male and two females) (7.69%) dropped out from the study group and six female patients (14.63%) dropped out from the control group (Figure [2](#F2){ref-type="fig"}). No adverse events were recorded in both groups and dropouts occurred for patients' decision.

No differences were observed between study and control group, considering anthropometrical variables (Table [1](#T1){ref-type="table"}). Only heart rate was significantly higher in the control than in the study group (*p* = 0.043).

The main cause of hypothyroidism was Hashimoto thyroiditis, occurring with similar incidence both in study and control group (71.8 and 73.2%, respectively; *p* = 0.916). Only two patients (4.88%) in the control group presented an iatrogenic hypothyroidism, due to total thyroidectomy or to radioiodine treatment. The majority of the patients was treated with branded LT~4~ (97.5% in both groups; *p* = 0.971) and only the tablet formulation was used. Among branded LT~4~, Eutirox^®^ was the mostly taken (94.9% in the study vs. 90.2% in the control group; *p* = 0.432). The remaining patients were treated with Tirosint^®^ (2.6% in the study group vs. 7.3% in the control group; *p* = 0.644).

The calculated compliance for probiotics ingestion was 79.2% in the study group.

Thyroid Hormones {#S3-1}
----------------

Thyroid-stimulating hormone, fT~3~, fT~4~ did not change between study and control group at each visit, as well as among visits in the two groups (Table [2](#T2){ref-type="table"}). The lack of significance was confirmed after adjustment for BMI and BSA or considering hormonal ratios (fT~3~/fT~4~, fT~3~/TSH, and fT~4~/TSH).

###### 

Thyroid axis hormonal measurements.

                              Reference range   Study group   Control group   *p* Value
  --------------------------- ----------------- ------------- --------------- -----------
  TSH (μIU/mL)                0.35--4.94                                      
  Baseline                                      2.37 ± 1.66   2.81 ± 1.88     0.308
  Visit 1 (treatment phase)                     2.35 ± 1.68   2.97 ± 3.38     0.565
  Visit 2 (treatment phase)                     2.17 ± 1.84   3.88 ± 7.57     0.344
  Visit 3 (follow-up phase)                     2.53 ± 3.08   2.84 ± 2.47     0.343
  Visit 4 (follow-up phase)                     2.23 ± 1.72   3.27 ± 4.24     0.344
  *p* value                   --                0.896         0.970           --
                                                                              
  fT~3~ (pg/mL)               1.7--3.7                                        
  Baseline                                      2.7 ± 0.3     2.6 ± 0.3       0.871
  Visit 1 (treatment phase)                     2.7 ± 0.4     2.7 ± 0.3       0.894
  Visit 2 (treatment phase)                     2.7 ± 0.4     2.7 ± 0.3       0.759
  Visit 3 (follow-up phase)                     2.6 ± 0.4     2.7 ± 0.3       0.079
  Visit 4 (follow-up phase)                     2.7 ± 0.4     2.7 ± 0.3       0.809
  *p* value                   --                0.873         0.592           --
                                                                              
  fT~4~ (pg/mL)               7--15                                           
  Baseline                                      10.8 ± 1.6    10.9 ± 1.6      0.902
  Visit 1 (treatment phase)                     10.9 ± 1.3    11.0 ± 1.6      0.850
  Visit 2 (treatment phase)                     10.9 ± 1.3    10.9 ± 1.6      0.962
  Visit 3 (follow-up phase)                     10.7 ± 1.2    10.9 ± 1.6      0.820
  Visit 4 (follow-up phase)                     10.9 ± 1.6    10.7 ± 1.7      0.424
  *p* value                   --                0.968         0.805           --

*Data are expressed as mean ± SD. p value is considered significant when \< 0.05*.

*fT~3~, free triiodothyronine; fT~4~, free tetraiodothyronine; TSH, thyroid-stimulating hormone*.

In the control group, TSH was inversely related to fT~4~ and fT~3~ (rho = −0.593, *p* \< 0.001 and rho = −0.293, *p* = 0.004, respectively) while fT~4~ and fT~3~ were directly related each other (rho = 0.269, *p* = 0.004), as expected according to TH physiology. Unexpectedly, the correlation between TSH and fT~3~ was lost after adjustment for age (*p* = 0.377) and BMI (*p* = 0.286). Similarly, TSH was inversely related to fT~4~ (rho = −0.547, *p* \< 0.001) in the study group, but their correlation to fT~3~ was absent (*p* = 0.516 and *p* = 0.462, respectively). However, in both groups, the correlation was lost when each visit was considered separately, suggesting that the low number of cases evaluated in subgroup analyses impaired the statistical power.

Regarding anthropometrical features at baseline, TSH was directly related to BMI (rho = 0.227, *p* = 0.047), but not to BSA (rho = 0.167, *p* = 0.146). Accordingly, fT~4~ was inversely related to BMI (rho = −0.260, *p* = 0.023), while fT~3~ did not correlate with any anthropometrical variable. Moreover, a direct correlation between TSH serum levels and systolic and diastolic pressures was found (rho = 0.282, *p* = 0.012 and rho = 0.227, *p* = 0.046, respectively). On the contrary, neither fT~4~ nor fT~3~ correlated with blood pressure. Similarly to what obtained for hormonal data, these relationships were lost considering following visits. Moreover, heart rate did not correlate to THs at any time point.

Evaluating the peripheral conversion of TH, the fT~3~/fT~4~ ratio was directly related to TSH at each visit in the control group, as expected for the known feedback mechanism. In the study group, this correlation was lost at visit 1 (rho = 0.287, *p* = 0.076), after one month of probiotics treatment, suggesting a possible probiotics effect on this central pathway.

LT~4~ Dose Adjustments {#S3-2}
----------------------

LT~4~ therapy was adjusted 10 times in 8 patients (10% of the total number of patients). In particular, LT~4~ doses were increased six times in four patients (the same patient needed three dosage adjustments) in the control group and decreased four times in four different patients in the study group (Table [3](#T3){ref-type="table"}). Dose adjustments were performed upon occurrence of alterations of serum TSH levels, as suggested by clinical guidelines ([@B40]). Interestingly, LT~4~ dose adjustments occurred more frequently in the control than in the study group (*p* = 0.007). However, the mean LT~4~ daily dose did not differ between groups (*p* = 0.419) and among visits (*p* = 0.916 in the control group and *p* = 0.970 in the study group). Considering patients with unchanged LT~4~ dose during the trial (90% of the total number of patients), the lack of hormonal changes after probiotic treatment remained.

###### 

Distribution of LT~4~ dose adjustments among groups.

                                    LT~4~ dose decrease   LT~4~ dose increase   Total
  --------------------------------- --------------------- --------------------- -------
  **All patients**                                                              
  Number of patients                4                     4                     8
  Times of LT~4~ dose adjustments   4                     6                     10
  **Study group**                                                               
  Number of patients                4                     0                     4
  Times of LT~4~ dose adjustments   4                     0                     4
  **Control group**                                                             
  Number of patients                0                     4                     4
  Times of LT~4~ dose adjustments   0                     6                     6

*LT~4~, levothyroxine*.

As expected, LT~4~ dose was directly related to fT~4~ in the study (rho = 0.299, *p* = 0.001) and control group (rho = 0.457, *p* \< 0.001), respectively. Moreover, LT~4~ dose was inversely related to TSH in the study (rho = −0.448, *p* \< 0.001) and control group (rho = −0.205, *p* = 0.029), respectively. Considering each visit separately these relationships remained. However, LT~4~ dose was not correlated with serum fT~3~ levels in any group (study group: rho = −0.041, *p* = 0.579; control group: rho = −0.079, *p* = 0.289).

Peripheral Tissue Markers {#S3-3}
-------------------------

All the peripheral tissue markers of THs evaluated did not change between groups or among visits (Table [4](#T4){ref-type="table"}).

###### 

Peripheral tissue markers of thyroid hormones.

                              Reference range      Study group    Control group   *p* Value
  --------------------------- -------------------- -------------- --------------- -----------
  CH (mg/dL)                  \<200                                               
  Baseline                                         219 ± 30       222 ± 37        0.626
  Visit 1 (treatment phase)                        226 ± 40       224 ± 39        0.780
  Visit 2 (treatment phase)                        213 ± 31       214 ± 48        0.898
  Visit 3 (follow-up phase)                        217 ± 39       219 ± 40        0.743
  Visit 4 (follow-up phase)                        220 ± 27       225 ± 45        0.582
  *p* value                   --                   0.496          0.853           --
                                                                                  
  CK (U/L)                    10--171                                             
  Baseline                                         93 ± 50        116 ± 10        0.658
  Visit 1 (treatment phase)                        77 ± 40        98 ± 77         0.240
  Visit 2 (treatment phase)                        77 ± 38        103 ± 75        0.085
  Visit 3 (follow-up phase)                        115 ± 137      107 ± 106       0.759
  Visit 4 (follow-up phase)                        81 ± 40        97 ± 86         0.864
  *p* value                   --                   0.636          0.840           --
                                                                                  
  Myoglobin (ng/mL)           15--106                                             
  Baseline                                         24 ± 11        25 ± 11         0.616
  Visit 1 (treatment phase)                        21 ± 8         23 ± 15         0.599
  Visit 2 (treatment phase)                        21 ± 6         23 ± 8          0.165
  Visit 3 (follow-up phase)                        23 ± 13        24 ± 10         0.368
  Visit 4 (follow-up phase)                        23 ± 7         24 ± 9          0.729
  *P* value                   --                   0.569          0.545           --
                                                                                  
  Ferritin (ng/mL)            25--400                                             
  Baseline                                         51 ± 61        44 ± 27         0.102
  Visit 1 (treatment phase)                        47 ± 53        43 ± 31         0.201
  Visit 2 (treatment phase)                        41 ± 43        47 ± 37         0.078
  Visit 3 (follow-up phase)                        40 ± 47        41 ± 31         0.222
  Visit 4 (follow-up phase)                        41 ± 41        41 ± 27         0.202
  *P* value                   --                   0.992          0.881           --
                                                                                  
  Lipoprotein(a) (mg/dL)      1--30                                               
  Baseline                                         21 ± 18        22 ± 28         0.516
  Visit 1 (treatment phase)                        21 ± 21        20 ± 25         0.406
  Visit 2 (treatment phase)                        19 ± 18        20 ± 25         0.547
  Visit 3 (follow-up phase)                        19 ± 19        17 ± 19         0.537
  Visit 4 (follow-up phase)                        22 ± 19        19 ± 25         0.238
  *p* value                   --                   0.967          0.980           --
                                                                                  
  Osteocalcin (ng/mL)         4.6--65.4                                           
  Baseline                                         16.0 ± 5.6     16.2 ± 5.2      0.832
  Visit 1 (treatment phase)                        15.4 ± 5.8     14.4 ± 6.5      0.475
  Visit 2 (treatment phase)                        15.1 ± 5.7     14.2 ± 7.1      0.557
  Visit 3 (follow-up phase)                        14.7 ± 6.5     14.7 ± 5.2      0.990
  Visit 4 (follow-up phase)                        14.4 ± 6.0     14.7 ± 6.2      0.879
  *p* value                   --                   0.826          0.598           --
                                                                                  
  ACE (U/L)                   8--52                                               
  Baseline                                         35 ± 13        33 ± 15         0.551
  Visit 1 (treatment phase)                        30 ± 11        31 ± 15         0.755
  Visit 2 (treatment phase)                        31 ± 12        29 ± 15         0.495
  Visit 3 (follow-up phase)                        32 ± 13        33 ± 21         0.820
  Visit 4 (follow-up phase)                        31 ± 12        32 ± 15         0.668
  *p* value                   --                   0.361          0.751           --
                                                                                  
  SHBG (nmol/L)               Female 19.8--155.2                                  
  Male 13.5--71.4                                                                 
  Baseline                                         78.9 ± 57.2    71.3 ± 41.3     0.981
  Visit 1 (treatment phase)                        70.5 ± 45.8    69.4 ± 41.4     0.992
  Visit 2 (treatment phase)                        74.3 ± 52.7    72.04 ± 42.2    0.915
  Visit 3 (follow-up phase)                        72.62 ± 55.7   72.0 ± 40.0     0.534
  Visit 4 (follow-up phase)                        78.5 ± 55.0    71.3 ± 37.9     0.806
  *p* value                   --                   0.951          0.994           --

*Data are expressed as mean ± SD. p value is considered significant when \< 0.05*.

*ACE, angiotensin-converting enzyme; CH, total cholesterol; CK, creatine kinase; SHBG, sex hormone-binding globulin*.

Considering baseline, TSH was directly related to CH (rho 0.278, *p* \< 0.001), CK (rho = 0.143, *p* = 0.007), myoglobin (rho = 0.134, *p* = 0.010), and ferritin (rho = 0.187, *p* \< 0.001) and inversely to SHBG (rho = −0.160, *p* = 0.002). FT~4~ was inversely related to CH (rho = −0.247, *p* \< 0.001) and myoglobin (rho = −0.112, *p* = 0.033) and directly to SHBG (rho = 0.211, *p* \< 0.001). FT~3~ was inversely related to lipoprotein(a) (rho = −0.185, *p* \< 0.001) and osteocalcin (rho = −0.105, *p* = 0.045). At visit 2, TSH remained directly related to CH (rho = 0.389, *p* = 0.017) and inversely to SHBG (rho = −0.326, *p* = 0.049). Accordingly, fT~4~ remained inversely related to CH (rho = −0.372, *p* = 0.025) and directly to SHBG (rho = 0.443, *p* = 0.007). These results confirm that CH and SHBG are the most significant tissue effectors of THs action.

Sixty patients were hypercholesterolemic (30 in the study group and 30 in the control group) at baseline, considering the proposed cutoff of CH \> 200 mg/dL. Considering only patients with high CH serum levels, peripheral tissue markers did not change among visits and between groups.

Multivariate Analyses {#S3-4}
---------------------

Stepwise multivariate linear analyses were performed considering TSH, fT~3~, and fT~4~ as dependent variables and anthropometrical parameters as independent. No significant models were generated in any group.

Discussion {#S4}
==========

Although the beneficial effects of probiotics were demonstrated in several physiopathological conditions, their impact on thyroid function in humans was not evaluated so far. Here, we found that the intake of a probiotic mixture does not alter directly LT~4~ therapy compensation in patients with primary hypothyroidism on substitutive treatment. Moreover, the probiotics-induced modification of intestinal bacteria seems to be not able to influence LT~4~ absorption when probiotics are administered at least 2 h after LT~4~ intake, since no hormonal serum variation was observed. While serum levels of TSH, fT~3~, and fT~4~ reflect drug absorption, the tissue markers analyzed in this study express THs action at the peripheral level. As a confirmation, no change after probiotics administration was observed. The lack of variation in both circulating hormone levels and THs tissue effect is consistent with the absence of differences in the therapeutic needs between groups and among visits. Nevertheless, a significant difference considering LT~4~ adjustments required in the two groups was found. Interestingly, controls needed significantly higher LT~4~ dose adjustments in comparison with cases, even if no changes in the mean LT~4~ daily dose occurred. We speculate that concomitant probiotics intake could increase the stability in thyroid function compensation. Thus, gut microbiota modification could allow an increased LT~4~ bioavailability, drawing from the THs intestinal reservoir through enterohepatic recycle. Indeed, the iodothyronines deconjugation is mediated by bacterial enzymes sulfatases and β-glucuronidases and the VSL\#3^®^ action on gut microbiota could influence the availability of these enzymes. However, in physiological conditions, enterohepatic recycle contributes minimally to circulating THs levels, since sulfated iodothyronines undergo rapid degradation by type 1 deiodinase ([@B17]) and deglucuronidation processes seem less important in humans than in animal models ([@B17]). This could be the reason of the lack of significant hormonal alterations in this population. However, it is not possible to exclude the presence of a "lessebo effect." This is described as a negative patients' expectation, related to the possibility of not receiving the "active" treatment ([@B42]). For this reason, control group patients were possibly less motivated to respect LT~4~ administration rules while probiotics-treated patients could have a higher motivation.

Regression analyses confirm the known correlations among THs and BMI. Considering peripheral tissue markers of THs, both TSH and fT~4~ are related with CH and SHBG levels, confirming that these markers are sensible to THs ([@B2]). Moreover, the fT~3~/fT~4~ ratio showed a direct correlation to TSH in the control group at each visit, according to physiological feedback mechanism. However, this relationship was lost in the study group after 1 month of probiotic treatment. Thus, probiotics should influence the deiodinases activity, temporarily reducing the feedback. This effect could be explained considering the known anti-inflammatory property of VSL\#3^®^, through the decrease in circulating pro-inflammatory cytokines ([@B43]). Thus, considering that deiodinases expression and activity can be modulated by cytokines ([@B44]--[@B48]), probiotics could interfere with THs deiodination. This result reinforces the hypothesis that VSL\#3^®^ is able to influence THs metabolism, although a final and significant difference in hormonal levels is not detected. Possibly, a longer treatment might be able to highlight these changes.

Even if VSL\#3^®^ is one of the most highly concentrated probiotics largely used in clinical trials, it does not contain strains expressing β-glucuronidases and sulfatases, which could directly increase the enterohepatic recycle of iodothyronines. However, contrasting data are available regarding *Lactobacilli* and *Bifidobacteria* effects on intestinal β-glucuronidase activity ([@B29], [@B49]). Thus, the VSL\#3^®^ modulation effect on microbiota by stimulating bacteria growth expressing β-glucuronidases and sulfatases may be only a speculation.

The main limit of this study is represented by the lack of placebo in the control group. It could limit the strength of our results, constituting a sort of "volunteer bias." Accordingly, the dropout rate is higher in the control than in the study group (six vs. three patients), although not significant. Secondly, the difficulty to evaluate probiotics treatment compliance is another notable limit. The sachets counting expresses an estimation of therapeutic compliance, but differences in microbiota composition and enzymatic activity before and after probiotics ingestion were not evaluated. Moreover, the compliance should be measured considering dietary assessment, which was not recorded in our trial. In the literature, several beneficial effects of VSL\#3^®^ were demonstrated, even if no precise evidence about the minimum probiotics concentration required to influence microbiota is available, representing a limit in all trials using probiotics. Furthermore, despite 2 months treatment period seems to be appropriate to modify gut microbiota ([@B50], [@B51]), it is not possible to confirm the exact time-interval needed to obtain a significant change in microbiota composition. Thus, further trials using higher probiotics concentration for longer time should be considered. Finally, in this setting, the accuracy of the TH assay methods remains a crucial point. Commonly used immunoassays could present discrepancies in TH measurement compared to the gold standard, liquid chromatography-tandem mass spectrometry (LC-MSMS), mainly due to pharmacological interferences or pathological conditions able to modify serum transport proteins ([@B52]). Nevertheless, the use of LC-MSMS is not currently routinely available in clinical practice and our study population does not present the common conditions that may undermine the immunoassay reliability.

In conclusion, this is the first randomized controlled trial evaluating possible interactions among probiotics, LT~4~ therapy, and pituitary--thyroid axis. Even if these results show no significant differences in hormonal parameters between groups and among visits, a possible probiotics interaction with THs homeostasis is proposed.

These data generate the hypothesis of a "stabilization" of LT~4~ treatment after probiotics ingestion, suggested by the reduced dose adjustments needed in the treatment group, as well as the need of a dose reduction observed only in subjects assuming probiotics. In particular, VSL\#3^®^ seems to be able to prevent hormonal fluctuations, perhaps modulating THs enterohepatic recycle and justifying the absence of differences in serum hormonal levels. The effect, however, is limited and no major clinical consequences can be proven at this stage.

The possible probiotics role as "LT~4~ therapy stabilizers" could be an endearing research starting point for both endocrinologists and investigators concerned with probiotics, in order to clarify the interaction between intestinal environment and endocrine system. This association was not evaluated so far and further studies should explore the relationship between gut microbiota and THs, considering other probiotic strains or longer treatment.
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